Anixa Biosciences (ANIX) Investor presentation summary

Business overview and financials

• Clinical-stage company focused on developing first-in-class cancer treatments and prevention products.

• Maintains a strong balance sheet with $15M in cash and short-term investments as of October 31, 2025.

• Operates a capital-efficient model with no debt, no warrants, and no preferred stock; annual cash burn of $5-7M.

• Consistent insider buying and a clean capital table with 33M shares outstanding.

• Leverages partnerships to develop programs and out-license or sell for late-stage development.

Clinical pipeline and partnerships

• Ovarian cancer CAR-T therapy (Lira-cel) in Phase 1 with Moffitt Cancer Center and The Wistar Institute.

• Breast cancer vaccine in Phase 1/2 with Cleveland Clinic; ovarian, lung, colon, and prostate cancer vaccines in pre-clinical stages.

• Collaborates with Cleveland Clinic, NIH, and National Cancer Institute for vaccine development.

• Utilizes advanced bioinformatics and AI for antigen target discovery.

CAR-T program for ovarian cancer

• Lira-cel targets FSHR, a receptor found primarily on ovarian cells and tumor vasculature.

• Dual mechanism: direct tumor cell killing and anti-angiogenesis by destroying tumor blood vessels.

• Intraperitoneal delivery keeps engineered T cells localized, minimizing systemic side effects.

• Phase 1 trial shows excellent safety, no dose-limiting toxicities, and promising survival in heavily pre-treated patients.